What the press reports about peptides - celebrities, longevity clinics and the protocols behind the headlines, every quote attributed and carrying no endorsement.
4 articles tagged “Culture & Press”
Peptides such as BPC-157, TB-500, Semax and Epitalon are moving from niche research circles into mainstream health news as the FDA prepares its July 2026 compounding review. Why it matters - and how to read the coverage responsibly, because a review is not an approval.
As peptides become a bigger public-health story around the FDA's July 2026 review, audiences need clearer information about BPC-157, TB-500, Semax, Epitalon and the 503A Bulks List. A plain-English guide to reading the coverage - FDA review is not FDA approval.
The cited version - BPC-157, NAD+, the “Wolverine stack” - with every quote attributed to ELLE, TIME, The Times, Yahoo and AOL. Reporting on press coverage, not endorsement.
The compounds Silicon Valley founders and A-list actors have cycled through for over a decade in $30,000-a-year longevity clinics - and how direct-to-researcher access changes the equation.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.